Claudiane Salles Daltio

A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial.

OBJECTIVE To evaluate the effects of 20 weeks of resistance and concurrent training on psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3, and brain-derived neurotrophic factor (BDNF) concentrations in patients with schizophrenia. METHODS In this blind, randomized controlled clinical trial, 34 patients with schizophrenia were assigned to one of three groups: control (CTRL, n=13), resistance exercise (RESEX, n=12), or concurrent exercise (CONCEX, n=9). Symptoms, quality of life, strength, and other variables were assessed. RESULTS A significant time-by-group interaction was found for the RESEX and CONCEX groups on the Positive and Negative Syndrome Scale (PANSS) total score for disease symptoms (p = 0.007), positive symptoms (p = 0.003), and on the arm extension one-repetition maximum (1RM) test (p = 0.016). In addition, significant improvements on negative symptoms (p = 0.027), on the role-physical domain of the Short Form-36 Health Survey (p = 0.019), and on the chest press 1RM test (p = 0.040) were observed in the RESEX group. No changes were observed for the other variables investigated. CONCLUSIONS In this sample of patients with schizophrenia, 20 weeks of resistance or concurrent exercise program improved disease symptoms, strength, and quality of life. ClinicalTrials.gov: NCT01674543.

Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo

OBJETIVO: Avaliar o custo direto medico-hospitalar da recaida em esquizofrenia, em servicos em saude mental. METODOS: Estudo conduzido em tres servicos de saude da cidade de Sao Paulo: um hospital publico estadual, um hospital contratado conveniado ao Sistema Unico de Saude e um centro de atencao psicossocial. Foram analisados 90 prontuarios de pacientes portadores de esquizofrenia atendidos durante o ano de 2006. Os recursos utilizados durante a permanencia dos pacientes nos servicos foram obtidos e valorados para calculos das estimativas. RESULTADOS: O custo direto medico-hospitalar medio da recaida em esquizofrenia, por paciente, foi de R

Estudos farmacoeconômicos e carga da doença em esquizofrenia

8.167,58 (US

Refractory schizophrenia: a neglected clinical problem

4,083.50) no hospital publico estadual, R

Knowledge in schizophrenia: The Portuguese version of KAST (Knowledge About Schizophrenia Test) and analysis of social-demographic and clinical factors' influence

4.605,46 (US

Custo direto médico-hospitalar de recaída em esquizofrenia em serviços de saúde na cidade de São Paulo

2,302.76) no centro de atencao psicossocial e de R

Costo directo médico-hospitalario de recaída en esquizofrenia en servicios de salud en la ciudad de Sao Paulo, sureste de Brasil

2.397,74 (US

Is Flunarizine a Long-Acting Oral Atypical Antipsychotic? A Randomized Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia

1,198.50) no hospital conveniado. O principal componente foi o custo com diarias (87% a 98%). O custo com medicacao diferiu quanto a utilizacao de antipsicoticos tipicos ou atipicos. O uso de atipicos foi maior no centro de atencao psicossocial. CONCLUSOES: O investimento em medicacoes antipsicoticas e em estrategias que diminuam a recaida e a necessidade de diarias nos servicos, especialmente hospitalares, sao justificaveis pela proporcao dos custos que estas representam. Tratar a recaida no centro de atencao psicossocial apresentou um custo intermediario, com o beneficio de nao privar o paciente do convivio familiar.OBJECTIVE To assess direct medical costs associated with schizophrenia relapses in mental health services. METHODS The study was conducted in three health facilities in the city of São Paulo: a public state hospital; a Brazilian National Health System (SUS)-contracted hospital; and a community mental health center. Medical records of 90 patients with schizophrenia who received care in 2006 were reviewed. Information on inpatient expenditures was collected and used for cost estimates. RESULTS Mean direct medical cost of schizophrenia relapses per patient was US

Willingness to Pay in Caregivers of Patients Affected by Schizophrenia.

4,083.50 (R

Poster #M263 CLOZAPINE PRESCRIPTION TO TREATMENT-RESISTANT SCHIZOPHRENIA PATIENTS IN COMMUNITY MENTAL HEALTH SERVICES IN SãO PAULO BRAZIL

8,167.58) in the public state hospital; US